← Back to Search

Dietary Supplement

Nicotinamide mononucleotide (NMN-C) for Healthy Subjects

N/A

Waitlist Available

Research Sponsored by Seneque SA

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Females of childbearing potential should be either sexually inactive (abstinent) for 60 days prior to the first dose of the study, throughout the study and for 30 days after completion of the study, or be using an acceptable methods of birth control.

BMI between 18.5 and 29.9 kg/m2; with a stable weight over the last 3 months (±2 kg).

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29

Awards & highlights

Study Summary

This trial is investigating the safety and effects of a 30-day course of nicotinamide mononucleotide (NMN-C) in healthy adults.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 hour post-dose on day 29 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety as measured by subject incident of treatment-emergent adverse events

Safety as measured by subject incident of treatment-emergent clinically significant changes in clinical laboratory safety tests.

Safety as measured by subject incident of treatment-emergent clinically significant changes in vital signs

Secondary outcome measures

Change from baseline in NAD+ and NMN concentrations in whole blood

Change from baseline in NAD+ metabolites concentrations in plasma

Change from baseline in NAD+ metabolites concentrations in urine

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: NMN-CExperimental Treatment1 Intervention

Healthy individuals receiving NMN-C

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Nicotinamide mononucleotide (NMN-C)

2021

N/A

~50

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Seneque SALead Sponsor

3 Previous Clinical Trials

237 Total Patients Enrolled

Dicentra Inc.Industry Sponsor

3 Previous Clinical Trials

260 Total Patients Enrolled

LGDIndustry Sponsor

6 Previous Clinical Trials

451 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do my characteristics meet the criteria to join this medical experiment?

"This clinical trial seeks to recruit 24 participants with healthy BMI between 18.5 and 29.9 kg/m2 that have maintained their weight for the past 3 months (±2kg). Furthermore, post-menopausal women must present evidence of amenorrhea for a year before being eligible; whereas females capable of bearing children are expected to abstain from sexual activity or use effective birth control methods in order to be included in the study. Additionally, all patients will need to adhere to dietary guidelines issued by an assigned nutritionist both during and after completion of the experiment as well as consuming pre-established meals prior specified visits."

Answered by AI

Is eligibility limited to those under the age of 25 for this experiment?

"This clinical investigation is open to individuals aged 18 and above, up to the age of 65."

Answered by AI

Are there still vacancies in this research program?

"According to clinicaltrials.gov, this research endeavour is not presently enrolling patients; the trial was advertised on August 5th 2021 and its information was last updated on May 31st 2022. Despite that fact, there are currently 839 other studies actively seeking participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

2021. "Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04910061.